



Pharmacy and Therapeutics (P&T) Committee Provider Update

FOURTH QUARTER 2017



Presbyterian Health Plan, Inc.
Presbyterian Insurance Company, Inc.

P&T Committee Decisions Effective Jan. 15, 2018

Dear Healthcare Practitioner: The Presbyterian Health Plan, Inc., and Presbyterian Insurance Company, Inc. (Presbyterian) P&T Committee meets quarterly to promote the appropriate use of drugs, maintain the Presbyterian formularies and support our network of practitioners. The P&T Committee met on Oct. 18, 2017, and we would like to share the decisions made at the meeting that affect our formularies and pharmacy benefits.

Drug Name	Centennial Care	Commercial	Metal Level Plans	Medicare*
Formulary Additions				
Aliqopa™ (copanlisib), 60 mg vial for injection	MB, PA	MB, PA	MB, PA	Tier 5, PA
atenolol/chlorthalidone (generic for Tenoretic®), 50/25 mg and 100/25 mg tablets <i>Added to Centennial Care formulary.</i>	Formulary	Tier 1	Tier 1	Tier 2
Austedo™ (deutetrabenazine), 6 mg, 9 mg, 12 mg tablets	PA, QL	Tier 4, PA, QL	Tier 4, PA, QL (2017) Tier 5, PA, QL (2018)	Tier 5, PA, QL, SP
Benlysta® (belimumab) for injection for subcutaneous use, 200 mg/mL single-dose prefilled auto-injector and single-dose prefilled syringe <i>Note: Benlysta is also available as 120 mg or 140 mg single-dose vials for IV infusion. The vials are currently covered on the formularies (MB, PA, SP).</i>	PA, QL, SP	Tier 4, PA, QL, SP	Tier 4, PA, QL, SP (2017) Tier 5, PA, QL, SP (2018)	Tier 5, PA, QL, SP
Besponsa™ (inotuzumab ozogamicin) injection for IV infusion, 0.9 mg single-dose vial	MB, PA	MB, PA	MB, PA	Tier 5, PA

*Medicare formulary changes may be pending approval from Centers for Medicare and Medicaid Services (CMS).

MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required.

Drug Name	Centennial Care	Commercial	Metal Level Plans	Medicare*
Formulary Additions (continued)				
Differin ® OTC (adapalene), 0.1% gel <i>Rx version will be removed from the Centennial Care formulary.</i>	AL (PA required for patients ≥ 40 years of age)	NF	NF	NF
fenofibrate (generic for Tricor®), 48 mg and 145 mg tablets	Formulary	Tier 1	Tier 1	Tier 3
guanfacine ER tablets (generic for Intuniv®), 1 mg, 2 mg, 3 mg, 4 mg	QL	Tier 1, QL	Tier 1, QL	Tier 4, QL
Idhifa ® (enasidenib), 50 mg and 100 mg tablets	NF	NF	NF	Tier 5, PA, QL, SP
Kisqali ® Femara ® Co-Pack (ribociclib; letrozole), 200/2.5 mg tablets	PA, QL	Tier 4, PA, QL	Tier 4, PA, QL (2017) Tier 5, PA, QL (2018)	Tier 5, PA, QL
Kymriah ™ (tisagenlecleucel-T), suspension for IV infusion	NF	NF	NF	Tier 5, PA (2018)
Lynparza ® (olaparib), 100 mg and 150 mg tablets <i>Note: Lynparza is also available as 50 mg capsules. The capsules are covered on the formularies (PA, QL).</i>	PA, QL	Tier 4, PA, QL	Tier 4, PA, QL (2017) Tier 5, PA, QL (2018)	Tier 5, PA (new starts), QL
Northera ® (droxidopa), 100 mg, 200 mg and 300 mg capsules <i>Added to the Metal Level Plan 2018 formulary.</i>	NF	NF	NF (2017) Tier 4, PA, QL (2018)	Tier 5, PA, QL
Nerlynx ™ (neratinib), 40 mg tablets	NF	NF	NF	Tier 5, PA, QL, SP
phendimetrazine CR (generic for Bontril Slow Release), 105 mg capsule <i>Added to Metal Level 2018 formulary.</i>	NF	NF	NF (2017) Tier 4, PA, QL	NF
Restasis MultiDose ™ (cyclosporine ophthalmic emulsion) 0.05% 5.5 mL multidose bottle	PA, QL	Tier 3, PA, QL	Tier 3, PA, QL (2017) Tier 4, PA, QL (2018)	NF
Tekturna ® (aliskerin), 150 mg and 300 mg tablets <i>Added to Metal Level Plan 2018 formulary.</i>	NF	NF	NF (2017) Tier 4, PA, QL (2018)	Tier 4, ST
tetrabenazine (generic for Xenazine®) 12.5 mg and 25 mg tablets	PA, QL, SP	Tier 4, PA, QL, SP	Tier 4, PA, QL, SP (2017) Tier 5, PA, QL, SP (2018)	Tier 5, PA, QL
New Generics – unless otherwise noted when a generic product becomes available the brand name product will be removed from the formularies.				
diazepam rectal gel (generic for Diastat® AcuDial™ and Diastat® Pediatric), 2.5 mg, 10 mg, 20 mg	ST, QL, AL	Tier 2, ST, QL, AL	Tier 2, ST, QL, AL	Tier 4, ST
eletriptan (generic for Relpax®), 20 mg and 40 mg tablets	NF	Tier 3, ST, QL	Tier 3, ST, QL (2017) Tier 4, ST, QL (2018)	Tier 4, ST, QL (2017) NF (2018)

*Medicare formulary changes may be pending approval from Centers for Medicare and Medicaid Services (CMS).

MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required.

Drug Name	Centennial Care	Commercial	Metal Level Plans	Medicare*
New Generics – unless otherwise noted when a generic product becomes available the brand name product will be removed from the formularies. (continued)				
mephalan (generic for Alkeran®), 2 mg tablets	Formulary	Tier 1	Tier 1 (2017) Tier 2 (2018)	Part B
moxifloxacin ophthalmic solution 0.05% (generic for Vigamox®)	NF	Tier 3	Tier 3 (2017) Tier 4 (2018)	Tier 4
prasugrel (generic for Effient®), 5 mg and 10 mg tablets	PA, QL	Tier 3, PA	Tier 3, PA (2017) Tier 4, PA (2018)	Tier 4, PA, QL
scopolamine transdermal patch (generic for Transderm Scop®), 1 mg/72 HR	NF	Tier 3	Tier 3 (2017) Tier 4 (2018)	Tier 4, QL
Other Formulary Changes				
Advair® HFA (fluticasone propionate-salmeterol), 45-21 mcg/act, 115-21 mcg/act, 230-21 mcg/act metered dose inhalers – <i>Removed from the Centennial Care formulary.</i>	NF	Tier 3, ST, QL	Tier 3, ST, QL (2017) Tier 4, ST, QL (2018)	Tier 4
Alphagan® P (brimonidine tartrate) 0.1% ophthalmic solution – <i>Step therapy requirement added to Commercial and Metal Level Plan formularies.</i>	ST	Tier 2, ST	Tier 2, ST (2017) Tier 3, ST (2018)	Tier 3
Aristada® (aripiprazole lauroxil), 441 mg, 662 mg, 882 mg, and 1064 mg extended release suspension for IM injection – <i>Prior authorization removed from Centennial Care, Commercial and Metal Level Plan formularies.</i>	SP	Tier 4, SP	Tier 4, SP (2017) Tier 5, SP (2018)	Tier 5, PA
Humulin® R U-500 (insulin human injection) – <i>Moved from Tier 3 to Tier 4 on Commercial and Metal Level Plan formularies.</i>	NF	Tier 4, ST, QL	Tier 4, QL (2017) Tier 5, QL (2018)	Tier 4
Matulane® (procarbazine), 50 mg capsules – <i>Moved from Tier 2 to Tier 4/Tier 5 on Metal Level Plan formularies.</i>	PA, SP	Tier 4, PA, SP	Tier 4, PA, SP (2017) Tier 5, PA, SP (2018)	Tier 5, PA, SP
memantine (generic for Namenda®), 5 mg and 10 mg tablets – <i>Step therapy requirement removed from Centennial Care formulary.</i>	QL	Tier 1, QL	Tier 1, QL	Tier 2

*Medicare formulary changes may be pending approval from Centers for Medicare and Medicaid Services (CMS).

MB = Medical Benefit, ME = Medical Exception, NF = Non-Formulary, PA = Prior Authorization Required, QL = Quantity Limits Apply, SP = Specialty Pharmacy Mandated, ST = Step Therapy Required.

REMINDER

Vaccines for Children

Presbyterian members under the age of 19 years may obtain vaccines through the Vaccines for Children Program (VFC). The VFC Program is a federally-funded program that covers vaccines recommended by the Advisory Committee on Immunization Practices. Vaccines are available through providers' offices and public health clinics registered as VFC providers.

Food and Drug Administration (FDA) Alerts from July to October 2017

For a full list of FDA alerts and additional information, see the FDA website at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts>

Cyclobenzaprine and amantadine by Apace Packaging – Recall [07/28/2017]

Apace Packaging voluntarily recalled one lot of cyclobenzaprine 5 mg tablets (50 count, unit dose, NDC #50268-190-15, Lot #16710) and one lot of amantadine 100 mg capsules (50 count, unit dose, NDC #50268-069-15, Lot #16710) to the retail level. This recall is due to a small number of cartons of cyclobenzaprine that were potentially mislabeled as amantadine capsules.

Pravastatin sodium tablets by International Laboratories – Recall [08/10/2017]

International laboratories voluntarily recalled one lot of pravastatin 40 mg tablets (Lot # 115698A). The product was labeled as pravastatin 40 mg but contained bupropion XL 300 mg tablets.

Lorazepam Oral Concentrate 2 mg/mL by Amneal Pharmaceuticals – Recall [08/16/2017]

Amneal Pharmaceuticals LLC voluntarily recalled 13 lots of lorazepam oral concentrate 2 mg/mL to the consumer level due to a defect in the dropper markings, which could result in dispensing more or less than the prescribed dose. A listing of the affected lot numbers may be found at the following website: <https://www.fda.gov/Safety/Recalls/ucm571787.htm>.

Keytruda (pembrolizumab) in patients with multiple myeloma – FDA Statement [08/31/2017]

The FDA informed the public, healthcare professionals and oncology clinical investigators about the risks of using Keytruda in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for patients with multiple myeloma. Two clinical trials (KEYNOTE-183 and KEYNOTE-185) were halted by the FDA when interim results from both trials demonstrated an increased risk of death for patients who received Keytruda combined with an immunomodulatory agent as compared to the control group.

Opioid Addiction Medications in Patients Taking Benzodiazepines or CNS Depressants – Drug Safety Communication [09/20/2017]

The FDA advised that buprenorphine and methadone (opioid addiction medications) should not be withheld from patients who also receive benzodiazepines or other medications that depress the central nervous system. The combined use of these medications increases the risk of serious side effects, and the harm caused by not treating opiate addiction can outweigh these risks. The FDA requires that drug labels for products that contain buprenorphine and methadone are updated with information on how to manage/reduce the risks of using these medications concomitantly.

Ocaliva (obeticholic acid) – Drug Safety Communication [09/21/2017]

The FDA issued a warning regarding the risk of administering the incorrect dose of Ocaliva to treat primary biliary cholangitis in patients with moderate to severe decreases in liver function, which can result in serious liver injury or death. The FDA is working with the manufacturer of Ocaliva, Intercept Pharmaceuticals, to address these safety concerns.

You can find Presbyterian formularies and updates, including restrictions (e.g., quantity limits, step therapy and prior authorization criteria) and preferences, online at:

<https://www.phs.org/providers/formularies/Pages/default.aspx>.

Current and past issues of the P&T Committee Provider Updates are available online at:
<https://www.phs.org/providers/contact-us/news-and-communications/Pages/default.aspx>.


Providers must register with Presbyterian to receive P&T Committee Provider Update via email. Presbyterian eNews registration is located at
<https://www.phs.org/providers/contact-us/news-and-communications/Pages/default.aspx>.

The Universal Practitioner and Provider Manual and Centennial Care Practitioner and Provider Manual are also available online at: <http://phs.org/ProviderManual> and include information about pharmacy benefits, the prior authorization process, generic substitution and requesting non-formulary medications based on medical necessity. A printed copy of the Centennial Care Practitioner and Provider Manual is available at no cost from Presbyterian by contacting your Provider Network Management relationship executive.

Formulary Search App

As a reminder, Presbyterian formularies are also accessible through the Managed Markets Insight & Technology, LLC (MMIT) Formulary Search App. No registration required.

Search from your desktop at www.FormularyLookup.com or download the free app today.



P&T Email Box

We would like to inform providers of a new way to request medication additions, deletions or other changes to the Presbyterian formularies. These types of requests may now be submitted to the ASK PHP P&T mailbox at askphppt@phs.org.

Contact Us

The changes to our formularies are based on requests from our practitioners and by the recommendations of the P&T Committee. We value your input. If you have any concerns, please contact Pharmacy Director Chad Valdez, RPh, at cvaldez4@phs.org or (505) 923-5530. You may also contact the author of this newsletter, Kendra Ward, PharmD., at kward2@phs.org or (505) 923-6967 Monday through Friday from 8 a.m. to 5 p.m. or contact the ASK PHP P&T mailbox at askphppt@phs.org.

Thank you for partnering with us to improve the health of patients, members, and communities we serve.